Cite
HARVARD Citation
Yang, J. et al. (n.d.). Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet oncology. 16 (2), pp. 141-151. [Online].